Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steffen Bauer

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Clinical Pharmacology and Therapeutics|April 17, 2002
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteersJulia Kirchheiner, Jürgen Brockmöller, Ingolf Meineke, et al.
Cardiology|June 27, 2008
Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apneaKonstanze Diefenbach, Kathrin Kretschmer, Steffen Bauer, et al.
Clinical Pharmacology and Therapeutics|August 2, 2003
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteersJulia Kirchheiner, Dirk Kudlicz, Christian Meisel, et al.
European Journal of Clinical Pharmacology|September 17, 2004
Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteersAndreas Johne, Elke S Perloff, Steffen Bauer, et al.
Epilepsy Research|March 11, 2009
Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal periodChristina Fotopoulou, Rebekka Kretz, Steffen Bauer, et al.
Pharmacogenetics|March 5, 2002
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteersJulia Kirchheiner, Steffen Bauer, Ingolf Meineke, et al.
Clinical Pharmacokinetics|March 10, 2004
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteersJulia Kirchheiner, Ingolf Meineke, Göran Müller, et al.
British Journal of Clinical Pharmacology|November 4, 2004
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patientsIngrid Mai, Elke S Perloff, Steffen Bauer, et al.
Clinical Pharmacology and Therapeutics|October 8, 2004
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interactionIngrid Mai, Steffen Bauer, Elke S Perloff, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patientsSteffen Bauer, Elke Störmer, Andreas Johne, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Clinical Pharmacology and Therapeutics|April 17, 2002
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteersJulia Kirchheiner, Jürgen Brockmöller, Ingolf Meineke, et al.
Cardiology|June 27, 2008
Endothelin-1 gene variant Lys198Asn and plasma endothelin level in obstructive sleep apneaKonstanze Diefenbach, Kathrin Kretschmer, Steffen Bauer, et al.
Clinical Pharmacology and Therapeutics|August 2, 2003
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteersJulia Kirchheiner, Dirk Kudlicz, Christian Meisel, et al.
European Journal of Clinical Pharmacology|September 17, 2004
Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteersAndreas Johne, Elke S Perloff, Steffen Bauer, et al.
Epilepsy Research|March 11, 2009
Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal periodChristina Fotopoulou, Rebekka Kretz, Steffen Bauer, et al.
Pharmacogenetics|March 5, 2002
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteersJulia Kirchheiner, Steffen Bauer, Ingolf Meineke, et al.
Clinical Pharmacokinetics|March 10, 2004
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteersJulia Kirchheiner, Ingolf Meineke, Göran Müller, et al.
British Journal of Clinical Pharmacology|November 4, 2004
MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patientsIngrid Mai, Elke S Perloff, Steffen Bauer, et al.
Clinical Pharmacology and Therapeutics|October 8, 2004
Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interactionIngrid Mai, Steffen Bauer, Elke S Perloff, et al.
British Journal of Clinical Pharmacology|February 13, 2003
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patientsSteffen Bauer, Elke Störmer, Andreas Johne, et al.
Pageof 5